Serum oncoproteins in asbestosis patients.
Using ELISAs, we determined the concentrations of transforming growth factor alpha (TGF-alpha), the extracellular domain of the erbB-2 receptor (erbB-2 ECD), and mutant p53 protein in stored serum samples of asbestosis patients with and without cancer and control subjects (without asbestosis or cancer). The percentage of individuals in these three groups with increased serum concentrations of TGF-alpha, erbB-2 ECD, and mutant p53, respectively, were: asbestosis patients with cancer, 36%, 16%, 19%; asbestosis patients without cancer, 38%, 19%, 6%; control subjects, 0%, 5%, 10%. Although differences in serum positivity for these oncoproteins were apparent among these groups, the differences did not achieve statistical significance (P > 0.05). In several of the cancer cases, increased concentrations of TGF-alpha, erbB-2 ECD, and mutant p53 were also detected in the stored serum samples collected years before the clinical diagnosis of disease.
D001195:Asbestosis / Q000097:blood* / Q000503:physiopathology; D015331:Cohort Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood; D008297:Male; D008654:Mesothelioma / Q000097:blood; D015513:Oncogene Proteins / Q000097:blood*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood; D016211:Transforming Growth Factor alpha / Q000097:blood; D016159:Tumor Suppressor Protein p53 / Q000097:blood
D015513:Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D016211:Transforming Growth Factor alpha; D016159:Tumor Suppressor Protein p53